Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals

Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2) caused by Covid-19 epidemics
have been implicated in 330,000 more than cases in Turkey and 40 health workers at a rate
close to 5% by thousand cases affected by this epidemic and There is a serious increase in
risk for people every day.

There is currently no established post-exposure prophylaxis for people at high risk of
developing COVID-19. Propolis, a natural resin produced by bees and of plant origin, has
anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the
SARS-CoV-2 infection mechanism are potential targets for propolis compounds. This work; It is
a randomized study aiming to evaluate the effect of Anatolian propolis extract against the
effects of the new coronavirus threatening human health. In this clinical study, the product
containing Anatolian propolis will be used to evaluate its effectiveness. According to the
spectrophotometic analysis report of this product, there should be a minimum phenolic 106.0
mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te
/ ml.

There is no prophylaxis for people at high risk of developing COVID-19. It is one of the
first clinical studies aiming to investigate the effect of Anatolian Propolis against
COVID-19. This study will test whether Anatolian propolis can be used to prevent the
development of COVID-19 in people at risk of COVID-19. If Anatolian Propolis has been shown
to reduce the risk of developing COVID-19 in people at high risk of infection, this could
help reduce the morbidity and mortality of the COVID-19 outbreak.

This study will be done in 2 centers. These centers are planned as Atatürk University Medical
Faculty Emergency Medicine Clinic and Rize Recep Tayyip Erdoğan University Emergency Medicine
Clinic. This work will be done entirely on a voluntary basis. The research subject will be
explained to the healthcare professionals (doctor, nurse, medical secretary) working in both
emergency medicine clinics and voluntary participation forms will be signed by the healthcare
professionals who agree to participate in the study. Health workers who agree to participate
in the study will be accepted as the study group, and healthcare professionals who do not
agree to participate in the study will be accepted as the control group. The study group will
be asked to take 20 drops of Propolis drop form twice a day in the morning / evening and the
control group will not receive any treatment and both groups will be followed. In this
process, patients diagnosed with COVID-19 will be determined.

For the diagnosis of COVID-19, PCR test positivity taken from the throat will be accepted.
The study will cover a period of 1 month and at the end of 1 month, patients diagnosed with
COVID-19 in the study and control groups will be compared. Thus, the protective properties of
Anatolian propolis will be determined.

The data obtained will be analyzed with the SPSS.20 program. Data will be given as
percentages and numbers. Shapiro-Wilk and Kolmogorov-Smirnov tests will be used to evaluate
whether the data are suitable for normal distribution. Independent samples t-test will be
used to compare data normally distributed between two independent groups, and the
Mann-Whitney U test will be used if the data are not normally distributed. Categorical
variables will be compared using Chi-square and Fisher tests. A value of p <0.05 will be
considered statistically significant.